IMMUNOVIROLOGICAL STUDIES OF FATAL INFECTIOUS-MONONUCLEOSIS IN A PATIENT WITH X-LINKED LYMPHOPROLIFERATIVE SYNDROME TREATED WITH INTRAVENOUS IMMUNOGLOBULIN AND INTERFERON-ALPHA

被引:44
作者
OKANO, M
PIRRUCCELLO, SJ
GRIERSON, HL
JOHNSON, DR
THIELE, GM
PURTILO, DT
机构
[1] UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68105
[2] UNIV NEBRASKA,MED CTR,DEPT PEDIAT,OMAHA,NE 68105
来源
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY | 1990年 / 54卷 / 03期
关键词
D O I
10.1016/0090-1229(90)90054-T
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have studied a 19-year-old male with X-linked lymphoproliferative syndrome (XLP) and infectious mononucleosis (IM) who was treated with high-dose immunoglobulin (500 mg/kg/day) and recombinant interferon (IFN)-α (2 × 106 IU/m2/day). Fulminant hepatitis was delayed; however, virus-associated hemophagocytic syndrome, cholestatic jaundice, and renal failure occurred terminally. Initially, nonspecific natural killer (NK) cell activity against K562 cells was normal but it gradually decreased. Although reactive T cells were markedly increased in his blood during the acute phase, spontaneous EBV-positive cell lines were easily established. Additionally, his mononuclear cells produced IFN-γ but not IFN-α prior to treatment. Based on results of in vitro studies, we conclude that both IFN-α and IFN-γ production are likely necessary for inhibiting EBV immortalization in vitro. Both IFN-α and -γ were produced in cultures of B95-8 EBV-infected mononuclear cells from EBV-seropositive healthy individuals. These results suggest that defective EBV-specific cytotoxic T cell activity accompanied with defective or discordant IFN-α and -γ production permitted the development of fatal IM in this patient. Combined treatment with immunoglobulin and IFN-α appeared to be partially effective during the early stage of this disease. © 1990.
引用
收藏
页码:410 / 418
页数:9
相关论文
共 10 条
[1]   CYCLOSPORIN-A PROMOTES SPONTANEOUS OUTGROWTH INVITRO OF EPSTEIN-BARR VIRUS-INDUCED B-CELL LINES [J].
BIRD, AG ;
MCLACHLAN, SM ;
BRITTON, S .
NATURE, 1981, 289 (5795) :300-301
[2]   EPSTEIN-BARR VIRUS-INFECTIONS IN MALES WITH THE X-LINKED LYMPHOPROLIFERATIVE SYNDROME [J].
GRIERSON, H ;
PURTILO, DT .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (04) :538-545
[3]  
KLEIN G, 1981, CANCER RES, V41, P4302
[4]   SYNERGISTIC INHIBITION OF EPSTEIN-BARR VIRUS - TRANSFORMATION OF LYMPHOCYTES-B BY ALPHA-INTERFERON AND GAMMA-INTERFERON AND BY 3'-AZIDO-3'-DEOXYTHYMIDINE [J].
LIN, JC ;
ZHANG, ZX ;
CHOU, TC ;
SIM, I ;
PAGANO, JS .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (02) :248-254
[5]  
Matthews D.E., 2016, USING UNDERSTANDING, V135, P194
[6]  
OKANO M, 1988, Clinical Microbiology Reviews, V1, P300
[7]   INTERFERON-GAMMA IN A FAMILY WITH X-LINKED LYMPHOPROLIFERATIVE SYNDROME WITH ACUTE EPSTEIN-BARR VIRUS-INFECTION [J].
OKANO, M ;
THIELE, GM ;
KOBAYASHI, RH ;
DAVIS, JR ;
SYNOVEC, MS ;
GRIERSON, HL ;
JAFFE, HS ;
PURTILO, DT .
JOURNAL OF CLINICAL IMMUNOLOGY, 1989, 9 (01) :48-54
[8]  
SHAPIRO RS, 1988, NEW ENGL J MED, V318, P1334
[9]   EPSTEIN-BARR-VIRUS INDUCED LYMPHOPROLIFERATION - IMPLICATIONS FOR ANTIVIRAL CHEMOTHERAPY [J].
SULLIVAN, JL ;
MEDVECZKY, P ;
FORMAN, SJ ;
BAKER, SM ;
MONROE, JE ;
MULDER, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (18) :1163-1167
[10]   X-LINKED LYMPHOPROLIFERATIVE SYNDROME - NATURAL-HISTORY OF THE IMMUNODEFICIENCY [J].
SULLIVAN, JL ;
BYRON, KS ;
BREWSTER, FE ;
BAKER, SM ;
OCHS, HD .
JOURNAL OF CLINICAL INVESTIGATION, 1983, 71 (06) :1765-1778